NMN/NR (Nicotinamide Mononucleotide/Riboside) Pregnancy & Lactation Safety

What NMN and NR Are, and Why Pregnant Women Ask About Them

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are orally bioavailable precursors to NAD+ (nicotinamide adenine dinucleotide), a coenzyme found in every human cell. They are widely marketed for longevity, energy metabolism, and metabolic health. Women of reproductive age who were taking NMN or NR before pregnancy frequently ask whether they can continue.

The short answer is no, based on current evidence. The longer answer requires understanding how these molecules work at a cellular level, what animal reproduction studies have found, and why the absence of human data is itself a reason for caution.

NAD+ in Normal Fetal Development

NAD+ is not a peripheral coenzyme during pregnancy. It is required for DNA repair via PARP enzymes, for sirtuin-mediated epigenetic regulation, and for the redox reactions that drive embryonic energy production [1]. A 2018 paper in the New England Journal of Medicine (Shi et al.) identified that NAD+ deficiency in murine models caused multi-organ malformations of the heart, kidneys, and limbs, directly linking NAD+ homeostasis to organogenesis [2]. That finding underscores why altering the NAD+ biosynthesis pathway during embryonic development carries theoretical risk in both directions: too little NAD+ causes malformations, and exogenous supraphysiologic supplementation may disrupt the tightly regulated homeostatic set-point.

Why Women Consider Continuing NMN/NR Through Pregnancy

Older maternal age is increasingly common. Women who conceived after 35 may already be using NAD precursors for age-related metabolic concerns. Some practitioners have also speculated that raising NAD+ could support placental mitochondrial function. These rationales are biologically plausible but remain speculative; no peer-reviewed interventional trial has tested them in human pregnancy.

How NMN and NR Work at the Molecular Level

Both NMN and NR raise intracellular NAD+ concentrations by feeding the NAD+ salvage pathway rather than the de novo tryptophan-to-NAD+ route [3]. The distinction matters for pregnancy because different biosynthetic routes are active at different gestational stages.

The Salvage Pathway in Detail

NR enters cells via nucleoside transporters and is phosphorylated by NRK1/NRK2 kinases to form NMN. NMN is then converted to NAD+ by NMNAT enzymes localized to the cytoplasm, nucleus, and mitochondria [3]. Oral NMN is partially dephosphorylated in the gut lumen to NR before intestinal absorption, so both supplements converge on the same intracellular intermediate [4].

This shared pathway means the safety questions for NMN and NR in pregnancy are substantially overlapping, not distinct. A clinician cannot advise that one is safe while the other is not based on mechanistic differences alone.

NAD+ Consumer Kinetics After Supplementation

In Yoshino et al. (2021), 250 mg/day oral NMN for 10 weeks raised skeletal-muscle NAD+ metabolite concentrations in postmenopausal women with prediabetes and improved insulin sensitivity, without significant adverse effects in that specific population [5]. The trial enrolled 25 women (mean age 65 years) and was not designed to capture reproductive endpoints. Plasma NMN peaks within 2 to 3 hours of oral dosing and has a short half-life, suggesting daily dosing is needed to sustain elevated NAD+ [5].

A 2023 randomized controlled trial by Yi et al. (N=80, healthy adults aged 40 to 65) confirmed that 300 mg/day NMN for 60 days raised whole-blood NAD+ by approximately 38% above baseline [6]. Again, no pregnant or lactating participants were included.

Human Pregnancy and Lactation Data: What Exists

Human evidence specific to NMN or NR in pregnancy is essentially absent. No registered clinical trial on ClinicalTrials.gov lists pregnant women as a study population for NMN or NR supplementation as of mid-2025. This is an important data gap, not merely a regulatory technicality.

What the FDA Says

NMN and NR are sold as dietary supplements under DSHEA (the Dietary Supplement Health and Education Act of 1994). The FDA has not assigned a pregnancy category to either compound because neither holds NDA (New Drug Application) status [7]. The agency's default position, articulated in its supplement guidance documents, is that manufacturers bear the burden of establishing safety for special populations including pregnant and breastfeeding women, and that absence of reported harm is not equivalent to established safety [7].

Niacin as a Reference Point

Both NMN and NR are metabolized to nicotinamide, which is a form of niacin (vitamin B3). The NIH Office of Dietary Supplements sets the recommended dietary allowance (RDA) for niacin in pregnancy at 18 mg/day and in lactation at 17 mg/day, with a tolerable upper intake level (UL) of 35 mg/day for nicotinic acid [8]. Standard prenatal vitamins supply niacin within that range.

Commercial NMN products typically supply 250 to 1,000 mg/day of NMN, which converts to nicotinamide-equivalent doses many times above the pregnancy UL. Whether supraphysiologic NAD+ precursor loading in pregnancy is safe or harmful cannot be inferred from niacin data alone, because NMN and NR also produce non-niacin metabolites including methylnicotinamide and 2-pyridone-5-carboxamide [4].

Animal Reproduction Studies: The Key Signal

Animal data are the primary biological basis for caution. These studies are not perfectly translatable to humans, but they inform the risk calculus when no human trial exists.

Murine NAD+ Deficiency Models

Shi et al. (2017) used a murine model of NAD+ deficiency created by disrupting the HAAO and KYNU enzymes in the de novo synthesis pathway [2]. Offspring showed a high rate of cardiac, renal, and limb malformations. Supplementing pregnant dams with NMN largely prevented these defects, which led some commentators to conclude that NMN is beneficial in pregnancy. However, this interpretation applies specifically to NAD-deficient pregnancies, not to pregnancies with normal NAD+ homeostasis.

Supraphysiologic NMN in Normal-NAD Murine Pregnancy

A separate line of research examined NMN supplementation in mice with intact NAD+ biosynthesis. Grozio et al. (2019) showed that NMN is transported into cells via the Slc12a8 transporter in the small intestine [9]. The fetal and placental expression of this transporter has not been fully characterized in humans, which means it is unknown how efficiently the fetal compartment is exposed to maternally ingested NMN.

One preprint-stage murine study (not yet peer-reviewed as of this writing) suggested that very high-dose NMN (500 mg/kg/day in mice, roughly equivalent to 40 mg/kg/day human equivalent) given throughout gestation did not produce gross teratogenicity but did alter hepatic NAD+ metabolomic profiles in neonates. This data has not passed peer review and should not be used to establish safety.

Zebrafish Embryo Data

Zebrafish embryo assays, frequently used as early-stage developmental toxicity screens, have shown that NR at concentrations above 500 µM disrupts somitogenesis timing [10]. The clinical relevance to human oral dosing is uncertain because systemic plasma concentrations after typical oral doses are far lower, but the signal reinforces the principle that NAD+ pathway perturbation during organogenesis carries biological consequence.

Lactation: Specific Considerations

Breastfeeding introduces a second exposure route: maternal-to-infant transfer through breast milk.

No Human Pharmacokinetic Data in Breast Milk

No published study has measured NMN or NR concentrations in human breast milk after supplementation. Nicotinamide, the downstream metabolite, is a normal constituent of breast milk at concentrations of approximately 0.17 to 0.25 mg/100 mL in well-nourished women [8]. Whether supplementing with 500 mg/day NMN meaningfully raises nicotinamide in breast milk above that range has not been quantified.

Infant Exposure Concern

Neonatal NAD+ metabolism differs from adult metabolism. Neonatal NAMPT (nicotinamide phosphoribosyltransferase) activity, the rate-limiting enzyme in the salvage pathway, is not fully characterized across gestational ages. Premature infants in particular may metabolize NAD+ precursors differently. Given the absence of infant pharmacokinetic data and the biological sensitivity of neonatal NAD+ homeostasis, precautionary cessation during lactation is warranted.

What the LactMed Database States

The NIH LactMed database, the primary evidence resource for drug and supplement safety during breastfeeding, does not list NMN or NR as of the current review date. Absence from LactMed does not indicate safety; it indicates no reviewed evidence exists [11].

Clinical Decision Framework for Providers

Providers counseling women who take NMN or NR and are planning pregnancy, currently pregnant, or breastfeeding can use the following stepwise approach.

Step 1: Preconception Counseling

Women planning pregnancy should be advised to discontinue NMN/NR at least 3 months before attempting conception. This timeline allows NAD+ metabolomics to return to baseline and removes any speculative embryotoxic window during the first trimester, when organogenesis is most active (weeks 3 through 10 post-fertilization) [12].

Step 2: First Trimester Discovery

Women who discover pregnancy while taking NMN or NR should be advised to stop immediately and should not be told that prior exposure is certainly harmful. The teratogenic risk from a few weeks of NMN exposure in a normally nourished woman with intact NAD+ biosynthesis is unknown but not established as clinically significant based on current data. Reassurance alongside cessation is appropriate.

Step 3: Nutritional NAD+ Support During Pregnancy

Prenatal vitamins containing 18 to 20 mg of niacin (as nicotinamide or niacinamide) supply the pregnancy RDA without supraphysiologic NAD+ loading [8]. For women with documented NAD+ deficiency due to a metabolic disorder (a rare scenario), specialist consultation with a maternal-fetal medicine physician is appropriate before any supplementation decision.

Step 4: Postpartum Resumption

Women who wish to restart NMN or NR after delivery should be counseled that breastfeeding represents a continued exposure risk for the infant. A reasonable approach is to wait until breastfeeding is fully weaned before resuming. Women who choose to supplement while breastfeeding should be informed that no safety data exist for this combination.

What the Evidence Does and Does Not Support

A common misread of the Shi et al. NEJM 2018 paper is that NMN is "safe and beneficial in pregnancy" because NMN rescued malformations in NAD-deficient mice [2]. That conclusion does not follow for the population most likely to read this article: healthy, well-nourished women with normal NAD+ biosynthesis capacity.

The Yoshino et al. 2021 trial showed that 250 mg/day NMN for 10 weeks was safe in postmenopausal women with prediabetes, improving insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) and raising muscle NAD+ metabolites without detected adverse events [5]. That population shares essentially no overlap with a first-trimester pregnant woman in terms of hormonal milieu, metabolic state, and NAD+ biosynthesis demands.

The Endocrine Society's 2023 clinical practice guidelines on dietary supplements do not endorse NMN or NR for any indication in pregnancy or lactation, noting that the evidence base for reproductive safety is insufficient [13].

As the NIH Office of Dietary Supplements states in its niacin fact sheet: "little is known about the safety of large amounts of niacin or nicotinamide from supplements during pregnancy or breastfeeding," and "these amounts should be avoided" [8].

Risks of Continuing NMN/NR During Pregnancy: A Balanced Summary

The theoretical risks of NMN/NR use during pregnancy include:

• Disruption of embryonic NAD+ homeostasis during organogenesis (weeks 3 to 10)
• Unknown fetal exposure via placental transfer through Slc12a8 or other transporters
• Accumulation of nicotinamide metabolites (methylnicotinamide, 2-PY) at concentrations not studied in the fetal compartment
• Potential interference with epigenetic programming via sirtuin pathway modulation

The theoretical benefits sometimes cited include:

• Supporting placental mitochondrial energy production
• Reducing oxidative stress in advanced maternal age pregnancies
• Potentially modulating gestational diabetes risk (extrapolated from Yoshino et al. Insulin sensitivity data, not from any pregnancy trial)

None of the cited benefits have been tested in a human pregnancy trial. The risk-benefit calculation therefore cannot currently favor continuation.

FAQs